Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

The Retinoblastoma Gene01:20

The Retinoblastoma Gene

4.0K
Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
4.0K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.4K
Abnormal Proliferation02:23

Abnormal Proliferation

4.4K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.4K
Negative Regulator Molecules01:23

Negative Regulator Molecules

35.1K
Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
35.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The rise and fall of SARM1 base-exchange inhibitors.

Communications chemistry·2026
Same author

Wild-Type Scandinavian Planarian-Derived Extracellular Vesicles Accelerate Skin Wound Healing in Burn and Mechanical Injuries.

ACS omega·2026
Same author

Activity of cefepime/enmetazobactam against highly multidrug-resistant bacterial isolates recovered from war-associated wounds in Ukraine.

JAC-antimicrobial resistance·2026
Same author

Systematic Application of a Cellular Thermal Shift Assay for Inferring Inhibitor Binding Affinity to 17βHSD13 in a Humanized Liver Homogenate.

Biochemistry·2026
Same author

The covalent docking software landscape: features and applications in drug design.

Briefings in bioinformatics·2025
Same author

Visible-Light-Driven Aqueous Polymerization Enables in Situ Formation of Biocompatible, High-Performance Organic Mixed Conductors for Bioelectronics.

Angewandte Chemie (International ed. in English)·2025

Related Experiment Video

Updated: May 24, 2025

Inducible and Reversible Dominant-negative DN Protein Inhibition
08:35

Inducible and Reversible Dominant-negative DN Protein Inhibition

Published on: January 7, 2019

8.3K

Targeting TUBG1 in RB1-negative tumors.

Lisa Lindström1, Jingkai Zhou1, Bruno O Villoutreix2

  • 1Molecular Pathology, Department of Translational Medicine, Lund University, Malmö, Sweden.

FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology
|February 28, 2025
PubMed
Summary
This summary is machine-generated.

A novel compound, L12, selectively targets tumor cells by inhibiting gamma-tubulin1 (TUBG1), a key player in microtubule dynamics. This approach shows promise for personalized cancer chemotherapy with reduced side effects.

Keywords:
RB1TUBG1cancerchemotherapy

More Related Videos

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

17.5K
Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

27.0K

Related Experiment Videos

Last Updated: May 24, 2025

Inducible and Reversible Dominant-negative DN Protein Inhibition
08:35

Inducible and Reversible Dominant-negative DN Protein Inhibition

Published on: January 7, 2019

8.3K
Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

17.5K
Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

27.0K

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Microtubule disruption is a cancer treatment strategy but causes toxicity.
  • Selective targeting of gamma-tubulin1 (TUBG1) offers a potential therapeutic avenue.
  • Understanding the TUBG1-E2F1-retinoblastoma protein (RB1) network is crucial for developing targeted therapies.

Purpose of the Study:

  • To investigate the therapeutic potential of selectively targeting TUBG1 in cancer treatment.
  • To elucidate the mechanism of action of a novel compound, L12, targeting the TUBG1-E2F1-RB1 network.
  • To evaluate the efficacy and safety profile of L12 in preclinical cancer models.

Main Methods:

  • Development and characterization of a novel compound, L12 (4-(6-((3-Methoxyphenyl)amino)pyrimidin-4-yl)-N,N-dimethylbenzenamine).
  • In vitro studies to assess L12's effects on TUBG1, E2F1, RB1, and procaspase 3 expression.
  • Evaluation of L12's cytotoxicity and apoptotic response in cancer cells.
  • In vivo studies using xenografted small cell lung cancer models to assess tumor growth inhibition and toxicity.

Main Results:

  • L12 enhanced RB1 expression and selectively targeted cells with impaired RB1 signaling.
  • L12-mediated cytotoxicity was dependent on E2F1-upregulated procaspase 3 expression.
  • L12 specifically inhibited TUBG1 without affecting TUBG2, unlike traditional tubulin agents.
  • L12 demonstrated reduced neuronal axonal toxicity compared to vincristine and inhibited tumor growth in vivo.

Conclusions:

  • L12 represents a promising TUBG1 inhibitor with potential for selective cancer chemotherapy.
  • The compound's mechanism involves the TUBG1-E2F1-RB1 network and E2F1-mediated apoptosis.
  • L12 shows potential for personalized chemotherapy with a favorable safety profile, minimizing adverse effects on healthy tissues.